Blog

QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer

Austin, TX, Aug. 25, 2021 - QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the U.S. Food and Drug Administration (FDA) has cleared QSAM’s investigational new drug (IND) application which allows...

QSAM Biosciences Receives Orphan Drug Designation from FDA for CycloSam® in the Treatment of Osteosarcoma

Austin, TX, Aug. 18, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the U.S. Food and Drug Administration (FDA) has approved QSAM’s application for Orphan Drug Designation of CycloSam® in...

QSAM Biosciences Receives Patents in Japan and Canada; Strengthens Licensed IP Portfolio in Key Markets

Palm Beach, FL, Aug. 11, 2021 - QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the countries of Japan and Canada have granted patents covering “high purity therapeutic bone agents” in connection...